143 related articles for article (PubMed ID: 16279774)
1. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
Reux B; Nevalainen T; Raitio KH; Koskinen AM
Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
[TBL] [Abstract][Full Text] [Related]
3. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
Markt P; Feldmann C; Rollinger JM; Raduner S; Schuster D; Kirchmair J; Distinto S; Spitzer GM; Wolber G; Laggner C; Altmann KH; Langer T; Gertsch J
J Med Chem; 2009 Jan; 52(2):369-78. PubMed ID: 19143566
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
6. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
8. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
El Bakali J; Muccioli GG; Renault N; Pradal D; Body-Malapel M; Djouina M; Hamtiaux L; Andrzejak V; Desreumaux P; Chavatte P; Lambert DM; Millet R
J Med Chem; 2010 Nov; 53(22):7918-31. PubMed ID: 20979417
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
[TBL] [Abstract][Full Text] [Related]
10. GPCR structure-based virtual screening approach for CB2 antagonist search.
Chen JZ; Wang J; Xie XQ
J Chem Inf Model; 2007; 47(4):1626-37. PubMed ID: 17580929
[TBL] [Abstract][Full Text] [Related]
11. Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists.
Saari R; Törmä JC; Nevalainen T
Bioorg Med Chem; 2011 Jan; 19(2):939-50. PubMed ID: 21215643
[TBL] [Abstract][Full Text] [Related]
12. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
13. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Worm K; Weaver DG; Green RC; Saeui CT; Dulay DM; Barker WM; Cassel JA; Stabley GJ; DeHaven RN; LaBuda CJ; Koblish M; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2009 Sep; 19(17):5004-8. PubMed ID: 19646869
[TBL] [Abstract][Full Text] [Related]
16. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
[TBL] [Abstract][Full Text] [Related]
17. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
18. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening.
Cavasotto CN; Orry AJ; Murgolo NJ; Czarniecki MF; Kocsi SA; Hawes BE; O'Neill KA; Hine H; Burton MS; Voigt JH; Abagyan RA; Bayne ML; Monsma FJ
J Med Chem; 2008 Feb; 51(3):581-8. PubMed ID: 18198821
[TBL] [Abstract][Full Text] [Related]
20. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
